ACHC · Acadia Healthcare

The thesis

Acadia Healthcare is modestly more likely than not to beat the S&P 500 over the next three months. On 4 November 2026 the company reported third-quarter adjusted earnings per share of $0.60 against a $0.46 estimate and raised full-year adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) guidance to $615–625 million. The year-end professional-liability review and the fourth-quarter results, expected in late February 2027, show whether that range holds.

The shares closed at $37.81 on 12 November 2026. That is 22.6% above the 3-month reference close of $30.83 on 14 August 2026, and above both the 50-day average of $30.24 and the 200-day average of $26.75. The market has priced in most of the guidance raise: Barclays' target is $35 (Equal-Weight), below the last close, and Cantor Fitzgerald's is $39 (Neutral).

Bullish and bearish views on Acadia Healthcare Company, Inc.

The bull case on Acadia Healthcare Company, Inc. (ACHC), in brief: guidance raised again. The bear case: Florida supplied part of the beat.

Bull case

• Guidance raised again. The 4 November 2026 release lifted adjusted EBITDA guidance to $615–625 million from $590–615 million, adjusted EPS to $1.70–1.80 from $1.45–1.60, and revenue to $3.44–3.46 billion from $3.40–3.45 billion (Form 8-K exhibit).
• Revenue and earnings beat. Third-quarter revenue was $895.3 million against $877.9 million expected, up 5.1% from a year earlier, and the 10-Q filed 4 November 2026 shows $851.57 million a year earlier (Benzinga; SEC filing).
• Core hospital metrics improved. Same-facility revenue rose 5.2% and same-facility adjusted EBITDA rose 6.1% to $228.8 million; admissions grew 6.6% and revenue per patient day grew 4.0% (Earnings Whispers, 4 November 2026).
• Newer facilities add earnings in 2027. Management expects about $60 million of incremental EBITDA in 2027 from the 16 acute facilities opened since 2023 (third-quarter call, 5 November 2026).
• Leverage is easing. Net debt was 3.9 times adjusted EBITDA at 30 September 2026, down from 4.1 times, with $163.3 million of cash (Form 8-K exhibit).
• Analysts raised targets after the report. Deutsche Bank lifted its target to $46 from $32 with a Buy rating on 9 November 2026. UBS moved to $45, and Guggenheim and RBC to $41 (Benzinga, 6 November to 9 November 2026).

Bear case

• Florida supplied part of the beat. Third-quarter adjusted EBITDA of $176.4 million included a $13.4 million Florida supplemental-payment accrual against $5.6 million assumed in guidance. Earnings Whispers estimates EBITDA without the surplus was roughly flat from $173.0 million a year earlier.
• Year-to-date earnings are lower. Nine-month adjusted EBITDA was $469.9 million against $509.1 million a year earlier, and third-quarter adjusted EPS of $0.60 compared with $0.72 (Earnings Whispers, 4 November 2026).
• Commercial payer mix is shrinking. Commercial insurance fell to 20.9% of the payer mix, about 400 basis points lower than a year earlier, and losses at newly opened acute facilities widened to $12.6 million from $4.8 million (Earnings Whispers, 4 November 2026).
• A liability review is pending. The professional and general liability actuarial review falls in the fourth quarter. The second quarter of 2026 carried a $28.6 million reserve adjustment (second-quarter results, 28 July 2026).
• Government inquiries are costly and unresolved. Government-investigation costs were about $18 million in the third quarter, per Earnings Whispers, and the Department of Justice and SEC matters remain open.

Price setup

The shares closed at $37.81 on 12 November 2026, down from $38.80 on 11 November 2026 and $38.61 on 9 November 2026. The 52-week intraday high is $39.70, set on 9 November 2026; the last close is 4.8% below it. The 52-week closing low is $11.68 on 16 January 2026.

The advance was steep. The shares closed at $34.79 on 5 November 2026, the first session after the report, and $37.00 on 6 November 2026. The 50-day average of $30.24 and the 200-day average of $26.75, both as of 12 November 2026, sit well below the price, so the shares have not yet been tested near those levels since the report.

Benzinga's 30 October 2026 item listed Acadia among highly shorted stocks. Short covering can extend a rise after good news and can reverse it when the news fades.

Catalysts ahead

• 10 December 2026: Final-approval hearing on the $12 million derivative-lawsuit settlement, U.S. District Court, Nashville. Court approval would close the settlement and put the governance reforms in place; the court may continue the hearing.
• ~31 December 2026 (est.): Year-end professional and general liability actuarial review. A reserve charge in the fourth-quarter review is the largest identified threat to the raised EBITDA range; timing of any disclosure is unconfirmed.
• ~25 February 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether the $615–625 million EBITDA range held after the actuarial review.

What would change the view

A daily close below $33.00, which would give back most of the rise that followed the 4 November 2026 report. Fiscal 2026 adjusted EBITDA guidance cut below the $615 million floor, or a new large professional-liability reserve charge, would also show the case failing.

The risks this note tracks, each with what would confirm it:

• A fourth-quarter professional and general liability actuarial review adds reserves, as the second quarter of 2026 did with a $28.6 million adjustment. Confirmed by: a reserve adjustment for expected settlements in a company 8-K, the fourth-quarter release or the 10-K.
• The third-quarter beat leaned on Florida supplemental payments, so core earnings may be weaker than the headline. Confirmed by: fourth-quarter adjusted EBITDA below the level implied by the $615–625 million guidance once Florida timing normalizes.
• Commercial payer mix, 20.9% in the third quarter of 2026, keeps eroding and pressures revenue per patient day. Confirmed by: commercial mix below 20.9% or revenue per patient day growth under the 4.0% reported for the third quarter.
• A federal resolution of the Department of Justice or SEC inquiries arrives with a large penalty. Confirmed by: an 8-K disclosing a settlement, consent decree or material accrual.
• The $105 million Fashion Valley verdict survives post-trial motions and appeal. Confirmed by: a trial-court denial of post-trial motions or an appellate affirmance disclosed by 8-K or in the 10-K.

What it trades with

Acadia runs behavioral-health hospitals. It trades with other facility-based providers and with Medicaid and state supplemental-payment policy, more than with insurers. Its volumes and payer mix respond to state budgets and commercial insurer contracting.

Company-specific legal and liability news has moved the shares more than sector moves. The December 2025 guidance cut on professional-liability costs produced the worst one-day fall since 2000, per Barron's. Because short interest is high, moves around earnings and legal headlines tend to be larger than the sector's.